|
A set of 61 GBM specimens for analyses of patient survival and the correlation between FABP7 and EGFR expression |
||||||||||
| Case # |
Diagnosis |
Age |
Survival (wk) |
Censor |
FABP7 Nu |
FABP7 Cyto |
New Category* |
EGFR IHC |
P53 IHC |
MIB-1 |
|
|
||||||||||
| 160 |
GBM |
29 |
253 |
1 |
0 |
0 |
0 |
0 |
0 |
16.3 |
| 381 |
GBM |
32 |
220 |
1 |
0 |
0 |
0 |
0 |
3 |
32.6 |
| 259 |
GBM |
35 |
412 |
1 |
0 |
2 |
0 |
0 |
3 |
5.9 |
| 495 |
GBM |
38 |
125 |
1 |
0 |
2 |
0 |
0 |
3 |
2.2 |
| 262 |
GBM |
39 |
75.571 |
1 |
0 |
1 |
0 |
0 |
3 |
12.7 |
| 322 |
GBM |
40 |
33.571 |
1 |
0 |
0 |
0 |
0 |
3 |
14.7 |
| 483 |
GBM |
41 |
18.4286 |
1 |
0 |
1 |
0 |
0 |
1 |
6.2 |
| 499 |
GBM |
43 |
26.143 |
1 |
0 |
0 |
1 |
2 |
1 |
10.8 |
| 198 |
GBM |
43 |
83 |
1 |
0 |
1 |
0 |
0 |
3 |
32.7 |
| 310 |
GBM |
43 |
66.143 |
1 |
0 |
2 |
0 |
0 |
0 |
33.6 |
| 307 |
GBM |
44 |
65.4286 |
1 |
0 |
1 |
0 |
0 |
3 |
29.1 |
| 497 |
GBM |
44 |
138.429 |
1 |
0 |
1 |
0 |
0 |
0 |
62.1 |
| 436 |
GBM |
45 |
151.286 |
1 |
0 |
0 |
0 |
0 |
1 |
6.6 |
| 212 |
GBM |
46 |
106.571 |
1 |
0 |
0 |
0 |
0 |
2 |
39.6 |
| 208 |
GBM |
49 |
68.429 |
1 |
0 |
1 |
0 |
0 |
1 |
23.1 |
| 8 |
GBM |
52 |
45.429 |
1 |
0 |
2 |
1 |
1 |
1 |
5.9 |
| 501 |
GBM |
53 |
115.571 |
1 |
0 |
0 |
0 |
0 |
3 |
47.5 |
| 330 |
GBM |
53 |
20.7143 |
1 |
0 |
1 |
0 |
0 |
2 |
36.5 |
| 446 |
GBM |
56 |
41.571 |
1 |
0 |
0 |
0 |
0 |
3 |
39.2 |
| 404 |
GBM |
56 |
68.857 |
1 |
0 |
2 |
0 |
0 |
3 |
36.1 |
| 288 |
GBM |
57 |
38.2 |
1 |
0 |
0 |
1 |
1 |
2 |
21.8 |
| 19 |
GBM |
58 |
80.429 |
1 |
0 |
2 |
0 |
0 |
3 |
6.1 |
| 292 |
GBM |
58 |
38.2 |
1 |
0 |
2 |
NA |
NA |
0 |
NA |
| 472 |
GBM |
60 |
36.714 |
1 |
0 |
0 |
0 |
0 |
0 |
52.6 |
| 286 |
GBM |
61 |
51.286 |
1 |
0 |
2 |
0 |
0 |
1 |
51.3 |
| 341 |
GBM |
61 |
39.286 |
1 |
0 |
2 |
0 |
0 |
3 |
75.2 |
| 135 |
GBM |
63 |
21.143 |
1 |
0 |
2 |
0 |
0 |
1 |
44.6 |
| 494 |
GBM |
63 |
47.2 |
1 |
0 |
2 |
1 |
1 |
NA |
NA |
| 426 |
GBM |
64 |
83.143 |
1 |
0 |
2 |
0 |
0 |
3 |
34.6 |
| 295 |
GBM |
65 |
58.429 |
1 |
0 |
2 |
0 |
0 |
3 |
22.1 |
| 260 |
GBM |
67 |
22.5 |
1 |
0 |
0 |
NA |
NA |
0 |
11.7 |
| 329 |
GBM |
67 |
58.5 |
1 |
0 |
2 |
NA |
NA |
NA |
NA |
| 321 |
GBM |
69 |
24.571 |
1 |
0 |
0 |
0 |
0 |
1 |
46.9 |
| 298 |
GBM |
72 |
22.429 |
1 |
0 |
0 |
0 |
0 |
1 |
27.5 |
| 309 |
GBM |
76 |
29.429 |
1 |
0 |
0 |
0 |
0 |
1 |
91.9 |
| 409 |
GBM |
15 |
149.714 |
1 |
1 |
2 |
2 |
0 |
3 |
25.4 |
| 254 |
GBM |
25 |
101.571 |
1 |
1 |
2 |
2 |
0 |
3 |
34.8 |
| 403 |
GBM |
35 |
58 |
1 |
1 |
2 |
2 |
0 |
1 |
37.9 |
| 192 |
GBM |
51 |
36 |
1 |
1 |
1 |
2 |
0 |
1 |
31.7 |
| 240 |
GBM |
53 |
8.143 |
1 |
1 |
2 |
2 |
0 |
3 |
49.2 |
| 124 |
GBM |
54 |
46.143 |
1 |
1 |
2 |
2 |
0 |
1 |
41.7 |
| 470 |
GBM |
56 |
81 |
1 |
1 |
2 |
NA |
NA |
0 |
35.5 |
| 408 |
GBM |
57 |
44 |
1 |
1 |
1 |
2 |
0 |
1 |
32.8 |
| 425 |
GBM |
57 |
15.143 |
1 |
1 |
1 |
3 |
1 |
1 |
31.3 |
| 279 |
GBM |
59 |
47.143 |
1 |
1 |
2 |
3 |
1 |
2 |
23.4 |
| 493 |
GBM |
68 |
49.5 |
1 |
1 |
2 |
NA |
NA |
NA |
NA |
| 471 |
GBM |
70 |
42.286 |
1 |
1 |
1 |
3 |
2 |
0 |
25.5 |
| 496 |
GBM |
70 |
55.857 |
1 |
1 |
1 |
3 |
2 |
0 |
21.8 |
| 245 |
GBM |
70 |
22.5 |
1 |
1 |
2 |
NA |
NA |
2 |
22 |
| 241 |
GBM |
32 |
33.143 |
1 |
2 |
0 |
2 |
0 |
3 |
25.6 |
| 261 |
GBM |
33 |
21.571 |
1 |
2 |
2 |
2 |
0 |
2 |
50.1 |
| 297 |
GBM |
43 |
107.571 |
1 |
2 |
2 |
3 |
1 |
2 |
32.9 |
| 323 |
GBM |
46 |
81 |
1 |
2 |
2 |
2 |
0 |
1 |
16.9 |
| 263 |
GBM |
47 |
33.286 |
1 |
2 |
2 |
3 |
2 |
3 |
17.8 |
| 90 |
GBM |
48 |
66.857 |
1 |
2 |
1 |
3 |
2 |
1 |
15.4 |
| 230 |
GBM |
50 |
17.714 |
1 |
2 |
2 |
2 |
0 |
1 |
35.8 |
| 227 |
GBM |
52 |
53.1429 |
1 |
2 |
2 |
3 |
1 |
1 |
43.1 |
| 325 |
GBM |
52 |
32.143 |
1 |
2 |
2 |
3 |
2 |
0 |
20.3 |
| 443 |
GBM |
55 |
59.286 |
1 |
2 |
1 |
3 |
2 |
1 |
39.7 |
| 296 |
GBM |
59 |
39 |
1 |
2 |
0 |
2 |
0 |
1 |
44.9 |
| 335 |
GBM |
75 |
18.143 |
1 |
2 |
2 |
2 |
0 |
1 |
27.5 |
|
*Based on nuclear FABP7 and EGFR immunoreactivity: dual negative as "0", nuclear FABP7-/EGFR+ as "1", nuclear FABP7+/EGFR- as "2", and dual positive as "3" NA, no IHC data available. | ||||||||||
Liang et al. BMC Cancer 2006 6:97 doi:10.1186/1471-2407-6-97 |
||||||||||